Ubs Group Ag Syndax Pharmaceuticals Inc Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Ubs Group Ag holds 146,438 shares of SNDX stock, worth $2.36 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

146,438

Previous 125,152 17.01%

Holding current value

$2.36 Million

Previous $2.57 Million 9.69%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$17.93 - $24.81 $381,657 - $528,105	21,286 Added 17.01%	146,438 $2.82 Million
Q2 2024 Aug 13, 2024	SELL	$18.82 - $23.79 $2.72 Million - $3.44 Million	-144,659 Reduced 53.61%	125,152 $2.57 Million
Q1 2024 May 13, 2024	SELL	$19.71 - $24.57 $413,712 - $515,724	-20,990 Reduced 7.22%	269,811 $6.42 Million
Q4 2023 Feb 09, 2024	BUY	$11.39 - $21.67 $2.45 Million - $4.67 Million	215,444 Added 285.9%	290,801 $6.28 Million
Q3 2023 Nov 09, 2023	SELL	$14.52 - $21.77 $542,452 - $813,305	-37,359 Reduced 33.14%	75,357 $1.09 Million
Q2 2023 Aug 11, 2023	BUY	$19.35 - $22.31 $85,159 - $98,186	4,401 Added 4.06%	112,716 $2.36 Million
Q1 2023 May 12, 2023	SELL	$20.66 - $28.98 $1.33 Million - $1.87 Million	-64,470 Reduced 37.31%	108,315 $2.29 Million
Q4 2022 Feb 08, 2023	SELL	$20.64 - $26.24 $2.33 Million - $2.96 Million	-112,747 Reduced 39.49%	172,785 $4.4 Million
Q3 2022 Nov 10, 2022	SELL	$18.51 - $24.79 $576,456 - $772,034	-31,143 Reduced 9.83%	285,532 $6.86 Million
Q2 2022 Aug 10, 2022	BUY	$13.64 - $19.48 $1.38 Million - $1.98 Million	101,511 Added 47.18%	316,675 $6.09 Million
Q1 2022 May 16, 2022	BUY	$14.84 - $22.15 $1.11 Million - $1.65 Million	74,647 Added 53.12%	215,164 $3.74 Million
Q4 2021 Feb 14, 2022	BUY	$15.23 - $22.47 $1.07 Million - $1.57 Million	70,004 Added 99.28%	140,517 $3.08 Million
Q3 2021 Nov 15, 2021	BUY	$13.87 - $19.8 $723,195 - $1.03 Million	52,141 Added 283.81%	70,513 $1.35 Million
Q2 2021 Aug 13, 2021	SELL	$13.42 - $25.18 $603,900 - $1.13 Million	-45,000 Reduced 71.01%	18,372 $315,000
Q1 2021 May 12, 2021	BUY	$19.28 - $24.59 $996,930 - $1.27 Million	51,708 Added 443.31%	63,372 $1.42 Million
Q4 2020 Feb 11, 2021	BUY	$15.1 - $26.44 $161,026 - $281,956	10,664 Added 1066.4%	11,664 $260,000
Q3 2020 Nov 12, 2020	SELL	$13.39 - $17.48 $389,153 - $508,021	-29,063 Reduced 96.67%	1,000 $15,000
Q2 2020 Jul 31, 2020	BUY	$8.94 - $20.98 $126,822 - $297,622	14,186 Added 89.35%	30,063 $446,000
Q1 2020 May 01, 2020	SELL	$6.65 - $12.03 $65,954 - $119,313	-9,918 Reduced 38.45%	15,877 $174,000
Q4 2019 Feb 14, 2020	BUY	$5.43 - $9.22 $21,665 - $36,787	3,990 Added 18.3%	25,795 $227,000
Q3 2019 Nov 14, 2019	BUY	$7.47 - $10.76 $120,535 - $173,623	16,136 Added 284.64%	21,805 $163,000
Q2 2019 Aug 14, 2019	BUY	$4.9 - $9.31 $17,978 - $34,158	3,669 Added 183.45%	5,669 $53,000
Q1 2019 May 14, 2019	SELL	$4.26 - $6.86 $36,077 - $58,097	-8,469 Reduced 80.9%	2,000 $11,000
Q4 2018 Feb 14, 2019	BUY	$3.6 - $8.42 $26,362 - $61,659	7,323 Added 232.77%	10,469 $47,000
Q3 2018 Nov 14, 2018	BUY	$6.33 - $8.08 $7,254 - $9,259	1,146 Added 57.3%	3,146 $25,000
Q2 2018 Aug 14, 2018	SELL	$6.93 - $14.63 $9,501 - $20,057	-1,371 Reduced 40.67%	2,000 $14,000
Q1 2018 May 15, 2018	BUY	$8.71 - $14.82 $11,941 - $20,318	1,371 Added 68.55%	3,371 $48,000
Q4 2017 Feb 14, 2018	SELL	$7.8 - $12.94 $2,823 - $4,684	-362 Reduced 15.33%	2,000 $18,000
Q3 2017 Nov 14, 2017	BUY	$10.9 - $12.73 $19,848 - $23,181	1,821 Added 336.6%	2,362 $27,000
Q2 2017 Aug 14, 2017	SELL	N/A	-932 Reduced 63.27%	541 $8,000
Q1 2017 Nov 14, 2017	BUY	N/A	1,473	1,473 $20,000

Others Institutions Holding SNDX

# of Institutions

227

Shares Held

88.3M

Call Options Held

1.01M

Put Options Held

692K

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $910M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account